ivosidenib

{
  "id": "MLC-T-ONC-004560",
  "term": "ivosidenib",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used alone or with other drugs to treat adults with certain types of acute myeloid leukemia, cholangiocarcinoma (a type of bile duct cancer), or myelodysplastic syndromes that have a mutation (change) in the IDH1 gene. It is also being studied in the treatment of other types of cancer. Ivosidenib blocks the protein made by the mutated IDH1 gene, which may help keep cancer cells from growing. It is a type of enzyme inhibitor and a type of targeted therapy. Also called Tibsovo.",
    "An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Upon administration, ivosidenib specifically inhibits a mutated form of IDH1 in the cytoplasm, which inhibits the formation of the oncometabolite, 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1-expressing tumor cells. IDH1, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG."
  ],
  "synonyms": [
    "Tibsovo",
    "IDH1 inhibitor AG-120"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/ivosidenib/"
}